Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

167.47
+1.911.15%
Post-market: 167.40-0.0700-0.04%19:57 EDT
Volume:1.52M
Turnover:255.16M
Market Cap:22.47B
PE:-47.80
High:170.81
Open:166.03
Low:166.03
Close:165.56
52wk High:191.05
52wk Low:61.00
Shares:134.20M
Float Shares:129.78M
Volume Ratio:0.72
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-100.84
PE(LYR):-50.44

Loading ...

Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion

TIPRANKS
·
Yesterday

Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer

Reuters
·
Yesterday

Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer

THOMSON REUTERS
·
Yesterday

Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call

Reuters
·
Yesterday

Guardant Health is Maintained at Overweight by Barclays

Dow Jones
·
Oct 07

Barclays Sticks to Its Buy Rating for Guardant Health (GH)

TIPRANKS
·
Oct 07

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

TradingKey
·
Oct 07

Movement Alert|Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally

Market Focus
·
Oct 06

Movement Alert|Guardant Health Inc. Rises 5.07% in Regular Trading, UBS Report Highlights Liquid Biopsy Tailwinds

Market Focus
·
Oct 06

Guardant Health reports COSMOS study published in Cancer Research Communications

TIPRANKS
·
Oct 05

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Reuters
·
Oct 05

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

GlobeNewswire
·
Oct 05

Guardant Health price target raised to $200 from $190 at Guggenheim

TIPRANKS
·
Oct 01

S&P 500 Futures Drop in Premarket Trading; Moog, AngloGold Ashanti Lag

Dow Jones
·
Sep 28

Guardant Health (GH) Receives a Buy from Bernstein

TIPRANKS
·
Sep 26

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Dow Jones
·
Sep 24

Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300

Reuters
·
Sep 18

US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee

Reuters
·
Sep 17

Guardant Health on Track for Record High Close

Dow Jones
·
Sep 17

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16